Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is currently facing performance pressure due to a cyclical bottom, with expectations for new products ramping up and a recovery in profitability [3][4] - In H1 2025, the company reported revenue of 720 million yuan, a year-on-year decline of 48.7%, and a net profit attributable to shareholders of 65.3 million yuan, down 84.5% year-on-year [3][4] - The decline in revenue is attributed to a slowdown in market demand for sunscreen agents, inventory digestion by downstream customers, and increased market competition leading to price reductions [3][4] - The company has adjusted its profit forecast for 2025-2027, expecting net profits of 240 million, 350 million, and 470 million yuan respectively, with year-on-year changes of -57.2%, +47.1%, and +32.3% [3][4] Financial Performance - In H1 2025, the company's revenue from cosmetic active ingredients, synthetic fragrances, and others was 540 million, 160 million, and 12 million yuan respectively, with year-on-year changes of -54.8%, -14.3%, and +24.5% [4] - The gross profit margin for these segments was 35.3%, 22.2%, and 20.3%, with year-on-year changes of -17.1 percentage points, +0.04 percentage points, and +27.9 percentage points [4] - The company's overall gross margin and net margin for H1 2025 were 32.05% and 8.75%, down 15.8 percentage points and 21.24 percentage points year-on-year [5] Business Outlook - The company is in the process of ramping up new products and upgrading existing products, with a completed annual production capacity of 12,800 tons of amino acid surfactants and ongoing technical upgrades for carbomers [5] - The construction progress of a new project in Malaysia for sunscreen products has reached 48.55%, with expectations for smooth production ramp-up [5] - The company anticipates that the recovery of orders and improvement in capacity utilization will enhance profit levels in the future [4][5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][4]. Core Views - The company's revenue for H1 2025 reached 2.578 billion yuan, a year-on-year increase of 0.89%, while the net profit attributable to shareholders was 950 million yuan, up 17.41% year-on-year. The net profit margin improved to 36.8%, an increase of 5.2 percentage points year-on-year [3][4]. - The company has a rich pipeline of new games and is actively exploring AI applications, which are expected to drive future growth. The anticipated net profits for 2025-2027 are projected to be 2.167 billion, 2.401 billion, and 2.649 billion yuan, respectively [4][6]. Financial Performance - In H1 2025, the gross margin was 82.4%, reflecting a year-on-year increase of 0.4 percentage points. The company achieved a net profit of 432 million yuan in Q2 2025, representing a 12.79% increase year-on-year [3][4]. - The company’s mobile gaming revenue for the first half of the year was 1.9 billion yuan, a decrease of 10% year-on-year, but new game launches are expected to provide a boost [4][5]. - The overseas revenue for H1 2025 was 200 million yuan, showing a significant year-on-year increase of 60% [4]. Product Pipeline and Growth Drivers - The company has over 14 games approved for release and more than 4 games in development, covering various genres such as RPG and SLG. Notable upcoming titles include "Dragon Valley World" and "Digital Monster: Source" [4][5]. - The company has secured exclusive operational rights for the "Legend Box," which is expected to enhance revenue streams significantly [4][5]. AI and IP Development - The company is actively developing its IP portfolio and exploring AI technology, with initiatives such as the launch of the "SOON" platform for automated content generation and the AI emotional companion application "EVE" [5][6]. - The introduction of the "Warm Star Valley Dream Journey" toy brand indicates the company's strategy to leverage its IP in various sectors [5]. Valuation Metrics - The projected P/E ratios for 2025-2027 are 22.2, 20.1, and 18.2 times, respectively, indicating a favorable valuation outlook [4][6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady operations in pig farming, with a recovery in profitability for its protein and oil businesses. The revenue for the first half of 2025 reached 8.847 billion yuan, a year-on-year increase of 10.68%, while the net profit attributable to shareholders was 338 million yuan, up 22.27% year-on-year. However, the net profit for Q2 2025 was 190 million yuan, reflecting a year-on-year decrease of 14.59% [3][4] - Due to the impact of pig price fluctuations, the profit forecasts for 2025-2027 have been revised downwards. The expected net profits for 2025, 2026, and 2027 are 677 million yuan, 913 million yuan, and 1.576 billion yuan, respectively, with corresponding EPS of 0.50 yuan, 0.67 yuan, and 1.15 yuan [3][4] Summary by Sections Pig Farming Business - The revenue from the pig farming business in H1 2025 was 2.849 billion yuan, a slight decrease of 0.95% year-on-year, with a gross margin of 11.78%, an increase of 1.55 percentage points year-on-year. The number of pigs sold was 1.5282 million heads, representing a year-on-year increase of 9.05%. The company aims to reduce the total cost to below 13 yuan per kilogram for the entire year [4] Feed Business - The feed business reported revenue of 2.434 billion yuan in H1 2025, down 14.24% year-on-year, with a gross profit of 246 million yuan, a decrease of 35.17% year-on-year. The sales volume was 1.3415 million tons, a slight decline of 0.58% year-on-year. Despite the drop in sales volume, the overall gross margin improved year-on-year [5] Corn Storage and Protein Oil Processing - The corn storage business generated revenue of 1.305 billion yuan in H1 2025, a significant increase of 72.32% year-on-year, with a gross margin of 3.51%, up 7.76 percentage points year-on-year. The protein oil processing business saw revenue of 1.449 billion yuan, a remarkable increase of 97.60% year-on-year, with a gross margin of 6.99%, up 5.35 percentage points year-on-year. These segments have contributed to the overall profit recovery [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown significant growth in pig production, leading to a substantial release of performance, with leather profit margins improving and overall operations trending positively [3][4] - For the first half of 2025, the company reported revenue of 3.717 billion yuan, a year-on-year increase of 66.49%, and a net profit attributable to shareholders of 181 million yuan, a year-on-year increase of 504.12% [3] - The company has adjusted its profit forecasts for 2025-2027, expecting net profits of 390 million yuan, 898 million yuan, and 1.743 billion yuan respectively, with corresponding EPS of 0.77 yuan, 1.76 yuan, and 3.42 yuan [3][4] Financial Performance - In H1 2025, the company's pig farming revenue reached 3.432 billion yuan, up 68.34% year-on-year, with pig sales of 1.9095 million heads, an increase of 74.47% year-on-year [4] - The total cost of pig production was 13.44 yuan per kilogram in H1 2025, with expectations to reduce this to below 12.8 yuan per kilogram in H2 2025 [4] - The leather business generated revenue of 101 million yuan in H1 2025, a year-on-year increase of 176.78%, with a gross margin of 4.76%, up 35.23 percentage points year-on-year [5] Financial Summary and Valuation Metrics - The company's total revenue is projected to grow from 4.041 billion yuan in 2023 to 13.433 billion yuan in 2027, with a compound annual growth rate of approximately 30.2% [7] - The net profit attributable to shareholders is expected to improve from a loss of 645 million yuan in 2023 to a profit of 1.743 billion yuan in 2027 [7] - The company's P/E ratio is projected to decrease from -16.8 in 2023 to 6.2 in 2027, indicating an improving valuation as profitability increases [7]

北交所信息更新 越南战略成效显著，2025H1 扣非净利高增 74%，数字化赋能提质增效 ——北交所信息更新 2025 年 09 月 02 日 投资评级：增持（维持） | 日期 | 2025/9/1 | | --- | --- | | 当前股价(元) | 39.30 | | 一年最高最低(元) | 46.27/9.46 | | 总市值(亿元) | 29.95 | | 流通市值(亿元) | 14.30 | | 总股本(亿股) | 0.76 | | 流通股本(亿股) | 0.36 | | 近 3 个月换手率(%) | 506.91 | 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 2025H1 公司营收 3.35 亿元，同比增长 38.37% 公司发布 2025 年半年报，2025H1，公司实现营收 3.35 亿元，同比增长 38.37%； 归母净利润 1,035.76 万元，同比下降 51.26%；扣非归母净利润 1,022.85 万元， 同比增长 73.94%。我们看好公司聚焦越南市场，实现规模效应和协同效应，增 强公司综合实力和市场竞争力。我 ...

Investment Rating - The investment rating for the biotechnology industry is "Positive" (maintained) [1] Core Insights - The small molecule GLP-1RA market is expected to provide new incremental space for weight loss and diabetes management, with significant interest from multinational corporations (MNCs) accelerating their involvement in this sector [7][25] - The leading product in the small molecule GLP-1RA space is Orforglipron from Eli Lilly, which has completed multiple global Phase III clinical trials and is positioned to submit a New Drug Application (NDA) in the second half of 2025 [25][26] - Domestic companies are making substantial progress in the small molecule GLP-1RA pipeline, with several candidates entering late-stage clinical trials, indicating strong potential for commercialization and international expansion [19][25] Summary by Sections 1. Development Prospects of Small Molecule GLP-1RA - Oral GLP-1 drugs offer advantages such as ease of use and high patient compliance, with over 75% of initial treatment patients preferring daily oral therapy [14] - The small molecule GLP-1RA market is characterized by low costs and flexibility in usage scenarios, with significant recent business development (BD) transactions [14][23] 2. MNCs Accelerating Small Molecule GLP-1RA Pipeline - Eli Lilly's Orforglipron is the fastest progressing small molecule GLP-1RA product globally, with three Phase III trials achieving primary endpoints [25][27] - Other major pharmaceutical companies like AstraZeneca and Roche are also advancing their small molecule GLP-1RA pipelines, with several candidates in Phase II trials [29][30] 3. Pharmacokinetic Characteristics Impacting Efficacy - Pharmacokinetic features are crucial for the efficacy of small molecule GLP-1RA, with companies exploring new formulations to enhance solubility and absorption [6][19] 4. Investment Recommendations - The report recommends several companies as potential beneficiaries in the small molecule GLP-1RA space, including Innovent Biologics, East China Pharmaceutical, and others, highlighting their strong clinical development and commercialization potential [7][19]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown a rapid recovery in performance in Q2 2025, with significant growth in contact lens sales [4] - Revenue for the first half of 2025 reached 787 million yuan, representing a year-on-year increase of 14.72%, while net profit attributable to the parent company was 213 million yuan, up 2.53% year-on-year [4] - The company has adjusted its earnings forecasts for 2025-2026, now expecting net profits of 434 million yuan in 2025 and 477 million yuan in 2026, with a new forecast for 2027 at 530 million yuan [4] Financial Performance - In Q2 2025, the company achieved revenue of 430 million yuan, a year-on-year increase of 14.44%, and a net profit of 121 million yuan, up 14.85% year-on-year [4] - The gross margin for the first half of 2025 was 65.25%, down 4.43 percentage points, while the net margin was 26.30%, down 2.75 percentage points [4] - The company’s contact lens business saw revenue of 236 million yuan in the first half of 2025, a significant increase of 28.89% [5] Business Segments - The artificial crystalline lens segment generated revenue of 345 million yuan in the first half of 2025, growing by 8.23%, with high-end products like "All View" multifocal lenses seeing rapid growth [5] - The company’s research and development expenses totaled 83 million yuan in the first half of 2025, representing 10.60% of revenue, with several products making progress in the approval process [6] Valuation Metrics - The current stock price corresponds to a price-to-earnings (P/E) ratio of 36.2 for 2025, 32.9 for 2026, and 29.6 for 2027 [4] - The projected revenue for 2025 is 1.645 billion yuan, with a year-on-year growth rate of 16.7% [8] - The company’s return on equity (ROE) is expected to be 14.2% in 2025, slightly decreasing to 13.6% by 2027 [8]

Group 1: Industry Perspective on Institutional Research - The overall number of institutional research engagements in the A-share market has shown a rebound, although it remains below the levels of 2024, indicating a recovery in research interest [2][14]. - In the past week, the top sectors by the number of institutional engagements were pharmaceuticals, machinery, electronics, power equipment, and basic chemicals, with notable increases in attention for machinery, pharmaceuticals, automobiles, computers, and electronics [3][21]. - For August, the total number of institutional engagements in the A-share market was 1,509, which is lower than the 2,050 engagements in the same month of 2024, reflecting a generally low level of engagement for the year [22][24]. Group 2: Individual Company Focus - Yunnan Copper, Aidi Te, and Meiyingsen were among the companies that received significant market attention, with Yunnan Copper having 12 engagements in the past week [30][31]. - Aidi Te has been frequently researched, with three engagements last week, focusing on its overseas strategy and positive outlook for future growth, reporting a 34% year-on-year increase in overseas revenue for the first half of 2025 [34][34]. - Oriental Tantalum's mid-year performance showed steady growth, prompting plans to expand production capacity to meet market demand, with two engagements last week [4][34].

计算机/软件开发 黑芝麻智能（02533.HK） 2025H1 亏损收窄，出海&机器人领域带来高成长性 2025 年 09 月 02 日 投资评级：增持（维持） | 日期 | 2025/9/1 | | --- | --- | | 当前股价(港元) | 18.520 | | 一年最高最低(港元) | 43.850/14.500 | | 总市值(亿港元) | 117.47 | | 流通市值(亿港元) | 117.47 | | 总股本(亿股) | 6.34 | | 流通港股(亿股) | 6.34 | | 近 3 个月换手率(%) | 97.09 | 股价走势图 数据来源：聚源 -60% -30% 0% 30% 60% 90% 2024-09 2025-01 2025-05 黑芝麻智能 恒生指数 相关研究报告 《自动驾驶产品及解决方案龙头，自 动驾驶&跨域计算双轮驱动成长—港 股公司首次覆盖报告》-2025.5.13 张可（分析师） 周勃宇（联系人） 风险提示：消费复苏不及预期、竞争加剧、监管变动、新业务拓展不及预期。 | 财务摘要和估值指标 | | | | | | | --- | --- | --- | --- | ...

Investment Rating - The investment rating for Shanghai Xinyang is maintained as "Buy" [1] Core Views - The company reported significant growth in both revenue and profit, with a year-on-year revenue increase of 35.67% to 897 million yuan and a net profit increase of 126.31% to 133 million yuan for the first half of 2025 [4][5] - The semiconductor business is a major contributor to this growth, with semiconductor revenue reaching 709 million yuan, up 53.12% year-on-year [5] - The company is optimistic about its long-term development in the multi-material platform, leading to an upward revision of profit forecasts for 2025-2027 [4] Financial Summary - Revenue for 2025 is projected at 2,007 million yuan, representing a 36.1% year-on-year growth [7] - The net profit for 2025 is estimated at 261 million yuan, reflecting a 48.3% increase compared to the previous year [7] - The gross margin for 2025 is expected to be 40.8%, while the net margin is projected at 13.0% [7] - The company's total assets are forecasted to reach 7,127 million yuan by 2025, with total liabilities of 2,378 million yuan [9] Business Development - The company is expanding its production capacity to 43,500 tons and investing 1.049 billion yuan in optimizing production lines [6] - A new project for producing 50,000 tons of key integrated circuit materials is planned, with a total investment of 1.85 billion yuan [6] - The semiconductor segment is expected to continue its growth trajectory, with various products achieving market share expansion and increased orders [5]